The integration of liquid biopsy into routine clinical practice marks a transformative advancement in the management of cancer patients, enabling a multidisciplinary and dynamic approach to diagnosis, treatment selection, and disease monitoring. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, liquid biopsy offers a minimally invasive alternative to conventional tissue biopsies, delivering real-time insights into tumor genetics and heterogeneity.

Tumor cells, due to their high proliferative activity, undergo apoptosis and necrosis, releasing fragments of tumor-derived DNA into the bloodstream. Thanks to advances in DNA sequencing technologies, these ctDNA fragments can now be detected and characterized with high sensitivity and specificity. This facilitates the identification of actionable mutations, the monitoring of treatment response, and the early detection of resistance mechanisms.

By enabling the non-invasive tracking of tumor evolution, liquid biopsy supports timely and personalized therapeutic decisions, potentially improving patient outcomes while minimizing the need for repeated invasive procedures. This approach is fully aligned with the principles of precision oncology, allowing treatment strategies to be rapidly adapted based on the tumor’s molecular profile at various stages of the disease.

This session will explore the latest evidence and practical considerations for implementing liquid biopsy in clinical oncology. Discussions will address technical, clinical, and organizational aspects essential for the effective integration of this tool into multidisciplinary cancer care pathways.